Drug class
L-type calcium-channel blocker; short-acting intravenous-class antiarrhythmic delivered intranasally
Mechanism of action
Blocks L-type calcium influx in cardiac tissue, slowing atrioventricular nodal conduction and interrupting re-entry circuits responsible for paroxysmal supraventricular tachycardia (PSVT).
General use cases
- Conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults using the intranasal CARDAMYST formulation, approved by the US FDA in December 2025
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
